Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV84ZR)

• Drug Name: CARTmeso/19 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Pancreatic cancer	2C10	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMV84ZR

Molecule-Related Drug Atlas

Drug(s) Targeting B-lymphocyte surface antigen B4 (CD19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[2]
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[3]
Axicabtagene ciloleucel	DMYHN59	Diffuse large B-cell lymphoma	2A81	Approved	[4]
Lisocabtagene maraleucel	DMP45ME	Large B-cell lymphoma	2A81	Approved	[5]
Inebilizumab	DMI0RHA	Neuromyelitis optica spectrum disorder	8E4A.0	Approved	[6]
Tecartus	DMYQCWT	Mantle cell lymphoma	2A85.5	Approved	[7]
Loncastuximab tesirine	DMXSVGI	Diffuse large B-cell lymphoma	2A81	Approved	[8]
Obexelimab	DMVIC4J	IgG4 related disease	4A43.0	Phase 3	[9]
MOR-208	DMDQOWT	Diffuse large B-cell lymphoma	2A81	Phase 2/3	[10]
CART-19	DMST3FM	Acute lymphoblastic leukaemia	2A85	Phase 2/3	[11]

Drug(s) Targeting Mesothelin (MSLN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CRS-207	DMXU5LZ	Gastric adenocarcinoma	2B72	Phase 2	[12]
MORAb-009	DMCXNIP	Mesothelioma	2C51.2	Phase 2	[13]
Anti-mesothelin CAR transduced PBL	DMXI03L	Cervical cancer	2C77.0	Phase 1/2	[14]
Anti-Mesothelin CAR-T cells	DM4NMBW	Gastric adenocarcinoma	2B72	Phase 1/2	[15]
CAR-T cells targeting Mesothelin	DMMAQJ7	Cervical cancer	2C77.0	Phase 1/2	[16]
Anti-Mesothelin CAR-T cells	DM4NMBW	Gastric adenocarcinoma	2B72	Phase 1/2	[17]
HPN536	DM86OJ0	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[18]
CAR-T cells targeting mesothelin	DMPK35H	Pancreatic cancer	2C10	Phase 1/2	[19]
TC-210	DM9S5I1	Cholangiocarcinoma	2C12.10	Phase 1/2	[20]
TC-510	DMSPG60	Breast cancer	2C60-2C65	Phase 1/2	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]
Mesothelin (MSLN)	TT4RXME	MSLN_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]

References

• [1] ClinicalTrials.gov (NCT03497819) Autologous CARTmeso/19 Against Pancreatic Cancer
• [2] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [3] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [8] Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
• [9] Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
• [10] A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
• [11] ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
• [12] Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015 Apr 20;33(12):1325-33.
• [13] Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36.
• [14] ClinicalTrials.gov (NCT01583686) CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
• [15] ClinicalTrials.gov (NCT03545815) Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.
• [16] ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
• [17] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [18] Clinical pipeline report, company report or official report of Harpoon Therapeutics.
• [19] ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
• [20] Clinical pipeline report, company report or official report of TCR2 Therapeutics.
• [21] Clinical pipeline report, company report or official report of TCR2 Therapeutics